Gathering Light

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-06-01-2001
Volume 0
Issue 0

I intended to write an entirely different column this month. Something like, What the Bush administration has done for you-the pharmaceutical industry-lately. Such as making it harder to do stem-cell research and pursuing an investigation into antigeneric activities. But something else happened. My father died. Now I have no room left in my mind or heart for other matters.

Articles in this issue
Industry Under Investigation
Covering the Bases
Emotion - The New Brand Integrator
For Love of the Game
Field of Dreams
Workshop: Access Options
Emotion - The New Brand Integrator
Rx-to-OTC: Unwanted Attention
Emotion - Biotech Renaissance Man
Biotech Renaissance Man
Relocation: Coming to America
Biotechnology: German Industry Beefs Up
Stocks: Catching the Market Blues
Gathering Light
Recent Videos
Marcel Botha, 10XBeta
Jennifer Kyle, Condor
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Related Content
March Pharmaceutical Industry Movers & Shakers

March Pharmaceutical Industry Movers & Shakers

Miranda Schmalfuhs
March 31st 2025
Article

A monthly roundup of business and people news in the pharmaceutical industry.

Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

Phase II Trial Shows Combination of Rybrevant Plus Lazcluze Significantly Reduces Moderate-to-Severe Skin, Nail Reactions in EGFR-Mutated NSCLC

Phase II Trial Shows Combination of Rybrevant Plus Lazcluze Significantly Reduces Moderate-to-Severe Skin, Nail Reactions in EGFR-Mutated NSCLC

Don Tracy, Associate Editor
March 31st 2025
Article

Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% compared to standard care in patients with epidermal growth factor receptor-mutated non-small cell lung cancer.

Jennifer Butler

The Misinformation Maze: Navigating Public Health in the Digital Age

Miranda Schmalfuhs
March 11th 2025
Podcast

Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.

Novo Nordisk Reaches Licensing Deal with Lexicon Pharmaceuticals for Novel Obesity Candidate

Novo Nordisk Reaches Licensing Deal with Lexicon Pharmaceuticals for Novel Obesity Candidate

Don Tracy, Associate Editor
March 28th 2025
Article

Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity and metabolic disorders.

Credit: WrightStudio | stock.adobe.com

Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success

Shana Gunderson Hua, PharmD; Nancy Pham, PharmD; and Pete Vaccaro
March 28th 2025
Article

The high-stakes nature of cancer care, coupled with rapid scientific advancements and increasing payer and regulatory pressures, demands a specialized approach beyond traditional market access strategies.